Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases.

Bayry J, Kaveri SV.

Trends Pharmacol Sci. 2018 Nov;39(11):919-922. doi: 10.1016/j.tips.2018.08.004. Epub 2018 Sep 7. Review.

PMID:
30201270
2.

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

Vaccaro C, Zhou J, Ober RJ, Ward ES.

Nat Biotechnol. 2005 Oct;23(10):1283-8. Epub 2005 Sep 25.

PMID:
16186811
3.

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N.

J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24.

4.

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.

Wang Y, Tian Z, Thirumalai D, Zhang X.

J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. Review.

PMID:
24404896
5.

Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

Ghetie V, Ward ES.

Annu Rev Immunol. 2000;18:739-66. Review.

PMID:
10837074
6.

Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.

Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V.

J Immunol Methods. 2013 Apr 30;390(1-2):81-91. doi: 10.1016/j.jim.2013.01.011. Epub 2013 Feb 4.

PMID:
23384837
7.

Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.

Burvenich IJ, Farrugia W, Lee FT, Catimel B, Liu Z, Makris D, Cao D, O'Keefe GJ, Brechbiel MW, King D, Spirkoska V, Allan LC, Ramsland PA, Scott AM.

MAbs. 2016 May-Jun;8(4):775-86. doi: 10.1080/19420862.2016.1156285. Epub 2016 Mar 30.

8.

Characterization and screening of IgG binding to the neonatal Fc receptor.

Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, Tiller T, Brocks B, Ostendorp R, Pabst S.

MAbs. 2014 Jul-Aug;6(4):928-42. doi: 10.4161/mabs.28744. Epub 2014 Apr 7.

9.

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.

Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z.

J Clin Invest. 2005 Dec;115(12):3440-50. Epub 2005 Nov 10.

10.

Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.

Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, Bitonti AJ.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2337-42. doi: 10.1073/pnas.0708960105. Epub 2008 Feb 12.

11.

Neonatal Fc receptor and IgG-based therapeutics.

Kuo TT, Aveson VG.

MAbs. 2011 Sep-Oct;3(5):422-30. doi: 10.4161/mabs.3.5.16983. Epub 2011 Sep 1. Review.

12.

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.

Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A.

MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353.

13.

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, Koch S, Papadimitriou A.

MAbs. 2013 Jul-Aug;5(4):576-86. doi: 10.4161/mabs.24981. Epub 2013 May 29.

14.

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Sockolosky JT, Szoka FC.

Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19. Review.

15.

The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Sesarman A, Vidarsson G, Sitaru C.

Cell Mol Life Sci. 2010 Aug;67(15):2533-50. doi: 10.1007/s00018-010-0318-6. Epub 2010 Mar 9. Review.

PMID:
20217455
16.

Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.

Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I.

J Biol Chem. 2012 Jun 29;287(27):22927-37. doi: 10.1074/jbc.M112.355131. Epub 2012 May 8.

17.

Antibodies in the breakdown lane.

Blumberg RS, Lencer WI.

Nat Biotechnol. 2005 Oct;23(10):1232-4. No abstract available.

PMID:
16211062
18.

FcRn: the MHC class I-related receptor that is more than an IgG transporter.

Ghetie V, Ward ES.

Immunol Today. 1997 Dec;18(12):592-8. Review.

PMID:
9425738
19.

FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS.

J Immunol. 2015 May 15;194(10):4595-603. doi: 10.4049/jimmunol.1403014. Review.

20.

Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.

Maeda A, Iwayanagi Y, Haraya K, Tachibana T, Nakamura G, Nambu T, Esaki K, Hattori K, Igawa T.

MAbs. 2017 Jul;9(5):844-853. doi: 10.1080/19420862.2017.1314873. Epub 2017 Apr 7.

Supplemental Content

Support Center